Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: photothermal therapy

August 27, 2026 Diagnosis / Drug delivery / Pharma applications

Revolutionary Nanozyme Microneedles for Gout Treatment

The Chinese group designed novel cyclodextrin-engineered bioinspired nanozyme (T-CD/Pt), and integrate it into a bi-regional microneedle (TP-MNs). Coupled with a

Continue reading

July 18, 2025 Drug delivery / Pharma applications

Hypoxia-responsive core-cross-linked supramolecular nanoprodrug based on dendritic drug-drug conjugates for synergetic anticancer therapy

A hypoxia-responsive dendritic drug-drug conjugates IR806-(Azo-CB)4 was prepared and combined with β-cyclodextrin-pendant poly(ethylene glycol)-block-poly(glutamic acid) block copolymer (PEG-PGlu-CD) to construct

Continue reading

September 25, 2023 CD as API / Drug delivery / Pharma applications

Application of Cyclodextrin for Cancer Immunotherapy

Tumor immunotherapy, compared with other treatment strategies, has the notable advantage of a long-term therapeutic effect for preventing metastasis and

Continue reading

August 14, 2023 Drug delivery / Pharma applications

Recent Advances for Dynamic-Based Therapy of Atherosclerosis

Atherosclerosis (AS) is a chronic inflammatory disease, which may lead to high morbidity and mortality. Currently, the clinical treatment strategy

Continue reading

March 4, 2022 Pharma applications / Supramolecular systems

β-Cyclodextrin-Derivative-Functionalized Graphene Oxide/Graphitic Carbon Nitride Composites with a Synergistic Effect for Rapid and Efficient Sterilization

The nonselectivity of phototherapy and the hydrophobicity of phototherapy agents limit their application in the treatment of antibiotic-resistant bacteria. In

Continue reading

Recent Posts

  • Bio-inks for skin regeneration: phase-adaptive design, multifunctional platforms, and 4D bioprinting frontiers
  • FermenGIN: γ-Cyclodextrin Takes the Bitterness Out of Bioconverted Red Ginseng
  • New book on beta-cyclodextrin and its derivatives
  • Moon, Water and Powdered Alcohol? A Footnote from NASA’s Lunar Life Support Studies
  • Enhancing Sunscreens: HPβCD Improves Ferulic Acid Efficacy

Tags

alpha-CD atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (28)
  • Analysis (75)
  • CD as API (359)
  • CD derivatives (440)
  • Cosmetics and toilettry (55)
  • Diagnosis (15)
  • Drug delivery (825)
  • E-ducation (64)
  • Environmental (144)
  • Events (242)
  • Food (239)
  • Gene delivery (22)
  • Household products (6)
  • In Hungarian (4)
  • Life sciences (46)
  • Non-pharma applications (427)
  • Other industrial use (114)
  • Pharma applications (1,232)
  • Supramolecular systems (45)
  • Uncategorized (173)

Top Posts

  • Bio-inks for skin regeneration: phase-adaptive design, multifunctional platforms, and 4D bioprinting frontiers
  • FermenGIN: γ-Cyclodextrin Takes the Bitterness Out of Bioconverted Red Ginseng
  • 22nd International Cyclodextrin Symposium (ICS-22) in India
  • 16th Central European Symposium on Pharmaceutical Technology (CESPT 2027)
  • Scientific Program of ICS22 India
  • Christmas cake with cyclodextrin
  • Pharmaceutics 2027 conference
  • Cyclodextrins without holes are reality
  • Lanosterol eye drops for cataract treatment
  • Cyclodextrin-assisted drug delivery to Central Nervous System: Mavenclad™ for multiple sclerosis treatment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,470 other subscribers
Loading Comments...